Fera, an Emerging Pharmaceutical Company, Acquires a Portfolio of Ophthalmic Ointments

Fera Pharmaceuticals has acquired all rights, title and interest to seven prescription sterile anti-infective ophthalmic abbreviated new drug applications (ANDAs) marketed by Fougera, a division of Nycomed US Inc. The products include Bacitracin; Bacitracin Zinc and Polymixin B Sulfate; Gentamicin Sulfate, Neomycin and Polymyxin B Sulfates and Bacitracin Zinc; Neomycin and Polymyxin B Sulfates and Dexamethasone; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Acetate as well Erythromycin Ophthalmic Ointments USP.

These seven products represent over 80% of the ophthalmic ointment market volume (source: IMS Health 2008).

Fera is pleased to be able to help meet the market demand for these important products and continue to provide physicians, pharmacies and patients more options when treating ocular infections.



Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying